Great team effort - one of the first to track neutralization of live virus by vaccine induced abs in myeloma

Great meeting for folks interested in immune engineering

Entertaining clash of current v future titans! RVD10000 v DRVD1000 u decode

Remarkably similar to the swog s0120 study. Need understanding of mm precursors in aa cohorts

Rockefeller lab reunion in beautiful sunny SF

Association of race/ethnicity with innate immune tumor microenvironment of children with B-ALL pubmed.ncbi.nlm.nih.gov/35710294/ excited to share this paper from my better half's group. Differences in innate immunity in children based on race/ethnicity and dz risk. need to look in MM

#IEgrc2022 Day 5 - ‘Cellular #Immunoengineering’ session talks by Wilson Wong (Boston University), Yvonne Chen (UCLA), Krishnendu Roy (Georgia Tech) & Li Tang (EPFL) focused on immune cell therapies for #cancer. Very engaging talks & stimulating questions from attendees. #grc

Great meeting! Emphasizing the power of connecting engineers and immunologists!

Congrats Mala!!!

Dr Marcela Maus puts #microenvironment in the Spotlight: “CAR-T in #Myeloma TME,” commenting on #CART therapy in myeloma, identified by Madhav Dhodapkar, Winship Cancer Institute of Emory University et al. bit.ly/3PYKtNQ MassGeneral News Harvard Medical School #mmsm #IMS2022

#IMS2022 Madhav Dhodapkar uncovers long PFS-associated features of #CARTcell and endogenous immune cells in #myeloma. Concurrent publication in Blood Cancer Discovery: bit.ly/3clqXO4 Commentary by Dr Marcela Maus: bit.ly/3cs5vH8 #mmsm #CARTcell

Immune cells beyond CAR T cells may impact the efficacy of BCMA-targeted CAR T-cell therapy, according to a study published in Blood Cancer Discovery. bit.ly/3CIGCBB Madhav Dhodapkar Winship Cancer Institute of Emory University Penn Penn Medicine News

Read related paper: Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA #CART Therapy in #Myeloma, by Madhav Dhodapkar, Kavita M. Dhodapkar et al. aacrjournals.org/bloodcancerdis… Winship Cancer Institute of Emory University #IMS2022

Congrats to Hope, Nancy and the team for the abstract being chosen for best of ASH2022

Impaired SARS-CoV-2 variant neutralization and CD8 T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections aacrjournals.org/bloodcancerdis… excited to share this work on booster vaccines in myeloma

Impaired neutralization and CD8+ #Tcell responses to current #SARSCoV2 variants of concern following 3x #mRNAvaccine in #myeloma: correlation with #COVID19 breakthrough infections, by Azeem, Madhav Dhodapkar et al. bit.ly/3j2s6Ns Winship Cancer Institute of Emory University Emory University #mmsm

Then and NowHarnessing Immunity in Myeloma: Wine That Keeps Getting Better? ashpublications.org/thehematologis…

doi.org/10.1172/JCI174… Excited to share new story on Treg mediated regulation of immune AE in melanoma pts after checkpoints. Collab with melanoma group Winship Cancer Institute of Emory University

Myeloma Paper of the Day, June 17th, suggested by Robert Z. Orlowski Joshua Richter, MD, FACP Dr. Jeffrey Zonder Mansi Shah Suzanne Lentzsch, MD, PhD Swathi Namburi @yariv_h Madhav Dhodapkar oncodaily.com/86696.html #Cancer #MyelomaPaperOfTheDay #OncoDaily #Oncology #Myeloma

JCI - Tregs protect against combination checkpoint blockade toxicity induced by Tph and B cell interactions- new insights into key players for checkpoint toxicity jci.org/articles/view/…